Home › Drug Use and Addiction › NCT06651333
fMRI and Opioid Abstinence
RecruitingObservational study
Functional Connectivity Mechanisms of Opioid Abstinence
Who can join
Ages 18 to 50 · All sexes
Full eligibility criteria
Inclusion Criteria: * recent initiation of methadone or buprenorphine at a clinic, program, or doctor within the past year (i.e., period of time during which treatment drop-out and risk for relapse is highest); * eligibility for MRI scanning; * ability to commit to study visits. Exclusion Criteria: * current acute psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5; * current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment; * severe cognitive impairment as determined via trained clinical research staff through consent process and during consent quiz or as indicated by a PROMIS Cognitive Function tscore \<30 (i.e., severe impairment) * past or present history of intellectual disability, developmental disorder, or neurological disease; * head trauma with loss of consciousness \>30 min; * organ dysfunction or any unstable or untreated medical conditions that may interfere with study participation.
About the study
This project examines functional connectivity patterns associated with subsequent relapse to illicit opioids during treatment for OUD.
What is being tested
- fMRI (diagnostic test)
Sponsor: Yale University · Participants: 240 · Started: Dec 12, 2024
Contact the study team
- Monica Holler · Phone: 203-278-1107
Official record on ClinicalTrials.gov — NCT06651333
Locations in the U.S.
| Connecticut | Hartford Healthcare, Hartford The APT Foundation, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.